Britannia Life Sciences Inc. (CSE:BLAB)
Canada · Delayed Price · Currency is CAD 0.0650
0.00 (0.00%)
Aug 7, 2026, 5:51 PM EST
Britannia Life Sciences Revenue
In the fiscal year ending March 31, 2026, Britannia Life Sciences had annual revenue of 474.83K CAD with 28.58% growth. Britannia Life Sciences had revenue of 127.84K in the quarter ending March 31, 2026.
Revenue
474.83K
Revenue Growth
+28.58%
P/S Ratio
22.21
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 474.83K | 105.56K | 28.58% |
| Mar 31, 2025 | 369.28K | -147.55K | -28.55% |
| Mar 31, 2024 | 516.83K | -5.89M | -91.93% |
| Mar 31, 2023 | 6.40M | -896.10K | -12.28% |
| Mar 31, 2022 | 7.30M | 5.88M | 412.42% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Devonian Health Group | 3.00M |
| Rapid Dose Therapeutics | 2.58M |
| Glow Lifetech | 2.22M |
| Pharmala Biotech Holdings | 1.27M |
| Kane Biotech | 58.57K |